Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

FDA Extends Parallel Review Program ‘Indefinitely’

Executive Summary

The program, which allows select manufacturers to have their products reviewed simultaneously for FDA approval and Medicare coverage, has been in the pilot stage since 2011. Now it is formally in full implementation mode and the agencies are looking for more manufacturers to participate.


Related Content

UK Health-Tech Assessor Signs On With FDA Payer Task Force
FDA, CMS Heads Press For 'Single Front Door' For Real-World Evidence
Exact Sciences Colon Cancer Test Gets Quick Results From CMS
Parallel Review Progress: FDA Approves, CMS Assesses Cologuard Cancer Test


Related Companies